Table 3.

Adverse effects measure according to the predicted CYP2D6 phenotype.

Adverse effects	EMs(N = 36)	IMs(N = 25)	Unknowns(N = 15)	Statistics	Adjusted P valuea
Weight change from week 0–4, kg	−0.41 ± 1.50	−0.59 ± 2.14	0.29 ± 1.14	1.263	0.289
Weight change from week 0–8	−0.63 ± 8.49	−4.50 ± 4.65	1.57 ± 3.36	2.231	0.116
GLU change from week 0–4, mmol/L	−0.24 ± 1.01	−0.65 ± 1.87	0.07 ± 1.21	1.239	0.296
GLU change from week 0–8	−0.14 ± 0.17	−0.11 ± 1.47	−0.06 ± 1.45	0.016	0.984
TG change from week 0–4, mmol/L	0.95 ± 1.30	0.01 ± 0.95	1.40 ± 1.12	7.099	0.002
TG change from week 0–8	0.26 ± 1.74	−0.14 ± 2.00	1.20 ± 1.28	3.540	0.035
CHO change from week 0–4, mmol/L	0.28 ± 1.28	−0.17 ± 1.17	0.65 ± 1.67	1.721	0.187
CHO change from week 0–8	0.14 ± 1.11	0.04 ± 0.99	0.63 ± 1.74	1.014	0.369
LDL change from week 0–4, mmol/L	0.26 ± 0.82	0.25 ± 0.75	0.44 ± 0.78	0.291	0.749
LDL change from week 0–8	0.20 ± 0.83	0.72 ± 0.87	0.44 ± 0.76	2.303	0.109
HDL change from week 0–4, mmol/L	−0.09 ± 0.26	−0.15 ± 0.31	−0.26 ± 0.22	0.911	0.407
HDL change from week 0–8	−0.05 ± 0.33	−0.07 ± 0.31	0.01 ± 0.46	0.219	0.804
PRL change from week 0–4, mmol/L	13.63 ± 33.29	23.95 ± 47.63	41.60 ± 60.64	1.921	0.155
PRL change from week 0–8	10.62 ± 34.60	25.15 ± 34.71	28.07 ± 56.18	1.191	0.311
ESRS Week 4	8(22.2%)	6(24.0%)	3(20%)	0.143	0.843
ESRS Week 8	7(19.4%)	4(16%)	3(20%)	0.038	0.963
BAS Week 4	2(5.5%)	1(4.0%)	1(6.7%)	0.870	0.424
BAS Week 8	3(8.3%)	1(4.0%)	1(6.7%)	2.037	0.729

Abbreviations: EMs, Extensive metabolizers; IMs, Intermediate metabolizers; GLU, glucose; TG, triglyceride; CHO, cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; PRL, prolactin; ESRS, Extrapyramidal Symptom Rating Scale; BAS, Barnes Akathisia Scale.

^aAdjusted P value after sex correction.